ArticleInternational journal of molecular sciences2018
Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Anti-NMDA Receptor Encephalitis, Human Papillomavirus, and microRNA.Current medicinal chemistry · 2025Pooled it
- Selective diagnostics of Amyotrophic Lateral Sclerosis, Alzheimer's and Parkinson's Diseases with machine learning and miRNA.Metabolic brain disease · 2025Article
- Distribution of microRNA Counts Across Human Chromosomes.Current medicinal chemistry · 2025Article
- MicroRNAs as potential biomarkers for diagnosis of attention deficit hyperactivity disorder.Neural regeneration research · 2024Review
- Differential Expression of MicroRNAs and Predicted Drug Target in Amyotrophic Lateral Sclerosis.Journal of molecular neuroscience : MN · 2023Article
- miRNA analysis reveals novel dysregulated pathways in amyotrophic lateral sclerosis.Human molecular genetics · 2023Article
- Epigenetic Changes in Prion and Prion-like Neurodegenerative Diseases: Recent Advances, Potential as Biomarkers, and Future Perspectives.International journal of molecular sciences · 2022Review
- The Role of Non-Coding RNAs in the Pathogenesis of Parkinson's Disease: Recent Advancement.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration.Current neuropharmacology · 2022Review
- Extracellular vesicles: A new paradigm in understanding, diagnosing and treating neurodegenerative disease.Frontiers in aging neuroscience · 2022Review
- Diagnostic Circulating miRNAs in Sporadic Amyotrophic Lateral Sclerosis.Frontiers in medicine · 2022Article
- RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective.International journal of molecular sciences · 2021Review
- Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study.Biomolecules · 2021Article
- MicroRNAs, Multiple Sclerosis, and Depression.International journal of molecular sciences · 2021Review
- Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis.Metabolic brain disease · 2021Review
- MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.International journal of molecular sciences · 2021Review
- Editorial: miRNAs and Neurological Diseases.Frontiers in neurology · 2021Article
- MicroRNA, Diabetes Mellitus and Colorectal Cancer.Biomedicines · 2020Review
- Small RNAs, Big Diseases.International journal of molecular sciences · 2020Review
- MicroRNAs and Apoptosis in Colorectal Cancer.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyotrophic lateral sclerosis (ALS) is among the severe neuro degenerative diseases that lack widely available effective treatments. As the disease progresses, patients lose the control of voluntary muscles. Although the neuronal degeneration is the cause of this disease, the failure mechanism is still unknown. In order to seek genetic mechanisms that initiate and progress ALS, the association of microRNA (miRNA) expression with this disease was considered. Serum miRNAs from healthy controls, sporadic ALS (sALS), familial ALS (fALS) and ALS mutation carriers were investigated. Principal component analysis (PCA)-based unsupervised feature extraction (FE) was applied to these serum miRNA profiles. As a result, we predict miRNAs that can discriminate patients from healthy controls with high accuracy. Thus, these miRNAs can be potential prognosis miRNA biomarkers for ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.